皓元医药：2025年净利润同比增长22.91%

Core Insights - The company, Haoyuan Pharmaceutical, announced a projected total revenue of 2,868.34 million yuan for 2025, representing a year-on-year growth of 26.35% [1] - The net profit attributable to the parent company's shareholders is expected to reach 247.77 million yuan, with a year-on-year increase of 22.91% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be 252.01 million yuan, reflecting a significant year-on-year growth of 40.82% [1] Financial Performance - As of the end of the reporting period, the company's total assets amounted to 6,210.95 million yuan, which is a 12.82% increase compared to the beginning of the reporting period [1] - The equity attributable to the parent company's shareholders is reported to be 3,145.19 million yuan, showing a growth of 9.29% from the start of the reporting period [1]